Trial Profile
Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Etoposide
- Indications Bladder cancer; Neuroendocrine carcinoma; Prostate cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Apr 2023 Status changed from recruiting to completed.
- 18 Feb 2023 Updated Results(n=14) assessing safety and efficacy signals of pembrolizumab and chemotherapy in patients with small cell/neuroendocrine cancer of the prostate and urothelium presented at the 2023 Genitourinary Cancers Symposium
- 23 Mar 2022 Planned End Date changed from 1 Sep 2023 to 1 Dec 2024.